Raul Romero Feregrino

Dr. Raul Romero Feregrino

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RRRaúl Romero-Cabello
Raúl Romero-Cabello
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
Valeria Magali Rocha RochaValeria Magali Rocha Rocha
Valeria Magali Rocha Rocha
RFRaul Romero Feregrino
Raul Romero Feregrino
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
Background: Influenza has continued to be an important public health challenge, and the WHO recommends that countries consider vaccination for persons at high risk. Mexico has such a program, and we sought to determine its current situation. Material and Methods: This study has an ecological, longitudinal, and retrospective design based on secondary information on the acquisition and application of vaccines against influenza from official data from 2006 to 2022. Results: We found annual variability in the numbers of purchases and application of doses, with coverage of less than 90% of the total population every year; in addition, 17 million vaccines were not used in this period. Discussion: This study shows the situation of the program at the national level. Two institutions acquired fewer the vaccines, while one purchased more for its target population, but the necessary vaccinations were not acquired. On average, 1.7 million of the vaccines purchased annually were not used, but in some years, more vaccines were applied than were purchased in all of the institutions. We also observed that, between institutions, the vaccine coverage was very different, from 21% to 180%. On average, 6.2 million people were not vaccinated annually, between 16% and 22% of the target population, demonstrating low coverage. When we compared the coverage data that we calculated to the data published by the institutions, a great difference was observed. Conclusions: We found inconsistencies in the data, indicating their unreliability and potential disorganization within the program, as the target populations of each institution were not clear. In addition, the application data may have had reporting errors. Adequate coverage was not achieved, and the coverage was different from that reported in the official sources. We propose the implementation of different systems for control, evaluation, and access to the information of the program.

2 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RRRaul Romero-Cabello
Raul Romero-Cabello
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
RFRaul Romero Feregrino
Raul Romero Feregrino
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
JAJulieta Isabel Aguilar-Feregrino
Julieta Isabel Aguilar-Feregrino
Background: In recent years in Mexico, a decreased Bacillus Calmette and Guérin (BCG) coverage has been observed concomitantly with new cases of tuberculosis. Material and Methods: This study is a descriptive and analytical evaluation regarding both BCG vaccine acquisition and coverage as reported by official sources over a 16-year period (2006–2021). Results: We found that vaccine acquisition, dose application and coverage are highly variable each year. Coverage is 90% or higher, except for the 2017–2020 period. Discussion: According to our calculations, between 3,917,616 and 4,961,868 individuals did not receive the BCG vaccine. Coverage was lower than 90% during the last 4 years, whereas this value decreased to 21% in 2020. Except for the last 5 years, the amount of acquired doses surpassed the demand thus causing a considerable vaccine wastage. Conclusions: BCG vaccine coverage is low and many individuals remain unprotected. The access to this vaccine is difficult and the number of newly reported cases of tuberculosis have increased during the last years. Thus, it is necessary to establish vaccination campaigns aimed protect the population and also to deploy a nominal system to control coverage, acquisitions, and target population.

RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RRRaúl Romero-Cabello
Raúl Romero-Cabello
RFRaul Romero Feregrino
Raul Romero Feregrino
PVPaulina Vilchis-Mora
Paulina Vilchis-Mora
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
Introduction: In 2008, Mexico initiated its national HPV vaccination program targeting adolescent girls. This study aims to evaluate the current status of the program, analyzing trends in vaccine acquisition, administration, and coverage over a 16-year period. Materials and Methods: A retrospective longitudinal study was conducted using secondary data from 2008 to 2023. Official records from three major public health institutions—IMSS, ISSSTE, and SSA—were reviewed to assess HPV vaccine procurement and administration. Results: Significant fluctuations were identified in the number of doses acquired, administered, and the corresponding coverage rates. A marked decline was observed between 2019 and 2021, followed by a sharp increase in 2022 and 2023. Over the entire period, an estimated 6.8 million doses were not administered to the intended target population. Furthermore, 2.6 million doses were administered in excess of the number officially acquired, indicating possible discrepancies in data reporting or vaccine inventory management. Discussion: The findings revealed substantial inconsistencies in vaccine procurement, administration, and coverage across institutions. While IMSS and ISSSTE consistently reported coverage below the theoretical target, SSA occasionally exceeded expectations, potentially compensating for deficits elsewhere. Nevertheless, national coverage remained inadequate in several years, with notable disparities between institutions. These gaps highlight systemic weaknesses in program coordination, planning, and data transparency, contributing to millions of unvaccinated individuals. Conclusions: This study offers a comprehensive analysis of Mexico’s HPV vaccination program, uncovering critical irregularities in its implementation. Challenges include inaccurate target population estimation, inconsistencies between vaccine acquisition and administration, and limited data reliability. Despite some progress in recent years, particularly in the post-pandemic years, the program requires urgent restructuring. This includes implementing a national catch-up strategy, expanding vaccine eligibility, and strengthening surveillance systems to ensure equitable and effective coverage toward the elimination of cervical cancer.

31 March 2023 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
RRRaúl Romero-Cabello
Raúl Romero-Cabello
RFRaul Romero Feregrino
Raul Romero Feregrino
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
SSSamuel Sevilla-Fuentes
Samuel Sevilla-Fuentes
Introduction: The impact of the coronavirus disease 2019 (COVID-19) pandemic has globally challenged health services, especially because when the pandemic first reached Mexico, in February 2020, there was no known effective and safe treatment. A treatment scheme was offered by the Institute for the Integral Development of Health (IDISA) in Mexico City from March 2020 to August 2021 when there were many patients with COVID-19. This report summarizes the experience managing COVID-19 with this scheme. Materials and Methods: This is a descriptive, retrolective study. The data was obtained from the case files of the patients who attended the IDISA from March 2020 to August 2021 with COVID-19. All the cases were treated with the scheme consisting of nitazoxanide, azithromycin, and prednisone. Various laboratory blood tests and chest computerized tomography scan were done. When indicated, supplementary oxygen, and another specific treatment were used. A standardized clinical recording was conducted for 20 days based on symptoms and systemic symptoms. Results: Based on the World Health Organization criteria, the patients were classified according to the disease severity: 170 mild, 70 moderate, and 312 severe cases. The outcome was the discharge of 533 patients after their recovery, 16 were excluded from the study, and 6 died. Conclusions: The use of nitazoxanide, azithromycin, and prednisone proved to be effective as it resulted in improvement of symptoms and in successful outcomes for the management of COVID-19 outpatients.

31 October 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RFRaul Romero Feregrino
Raul Romero Feregrino
RRRaul Romero-Cabello
Raul Romero-Cabello
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
BMBenjamin Madrigal-Alonso
Benjamin Madrigal-Alonso
Valeria Magali Rocha RochaValeria Magali Rocha Rocha
Valeria Magali Rocha Rocha
Background: In Mexico, the measles vaccine was first introduced in 1971. The last case of measles acquired through endemic transmission was recorded in 1995. In 1998, the monovalent measles vaccine was replaced by the combined measles–mumps–rubella (MMR) vaccine. The MMR vaccination schedule consists of two doses: the first is administered at 12 months of age, and the second is administered at either 18 months or 6 years of age. Materials and Methods: A retrospective analysis was conducted using secondary data from 2006 to 2024. Vaccine procurement and administration records from IMSS, ISSSTE, and SSA were reviewed to evaluate the performance of both the MMR and MR programs, focusing particularly on the trends in coverage and data consistency across institutions. Results: The analysis revealed persistent inconsistencies between vaccine procurement and administration for both the MMR and MR vaccines across all institutions. Several years exhibited notable mismatches, including surpluses and deficits in the administered doses relative to their procurement. Between 2006 and 2024, only 69 million of the 91.6 million required MMR doses were administered in Mexico, leaving a deficit of approximately 22.5 million doses (25% of the target population). For MR, a cumulative deficit of approximately 24.6 million procured but unadministered doses was identified. National coverage remained suboptimal, with significant variability across years and institutions. Comparisons with WHO and ENSANUT data indicated marked discrepancies. The seroprevalence findings, along with the 2025 measles outbreak, confirm significant gaps in immunity. Discussion: This study highlights systemic challenges in Mexico’s MMR vaccination program, including inconsistencies in vaccine procurement, administration, and reported coverage across institutions. Overestimated official MMR coverage rates and unclear target definitions for MR contribute to program inefficiencies and missed vaccination opportunities. The resurgence of measles in 2025, along with persistently high incidences of mumps, aligns with the observed immunity gaps, although a direct causal relationship cannot be established from this study. These findings are consistent with previous national studies and seroprevalence data. Conclusions: Despite limitations in the data, this study effectively evaluated the performance of Mexico’s MMR vaccination program, identifying critical gaps in coverage, data reliability, and operational alignment. The findings underscore the need for improved procurement planning, harmonized coverage estimates, and robust monitoring systems. To address the existing gaps in immunity, catch-up campaigns should prioritize the use of the MMR vaccine over MR. Strengthening nominal coverage tracking and implementing evidence-based strategies are essential to restoring public trust and maintaining the goals of measles elimination.

16 August 2025 in Cureus
Verified
Journal Article
Open access
PDF file
RFRaul Romero Feregrino
Raul Romero Feregrino
DRDaniel O. Pacheco Rosas
Daniel O. Pacheco Rosas
ACArantxa Juárez Castillo
Arantxa Juárez Castillo
MCMelissa Takashima Castro
Melissa Takashima Castro
JRJuan M. Ruíz Ruíz
Juan M. Ruíz Ruíz
DRDaniel Pacheco Rosas
Daniel Pacheco Rosas
Aeromonas salmonicida is a Gram-negative, oxidase-positive, facultative anaerobic bacterium primarily recognized as a pathogen in fish. Its isolation in humans is rare and scarcely reported, particularly in cases of peritonitis. We present the case of a 16-year-old female patient with end-stage chronic kidney disease, recent renal graft rejection, and undergoing continuous ambulatory peritoneal dialysis, who presented with severe abdominal pain and cloudy peritoneal effluent. Fluid analysis revealed an elevated leukocyte count (15,022 cells/μL, including 13,330 polymorphonuclear cells). Empirical treatment with cefalotin and amikacin was initiated. Following the observation of short Gram-negative bacilli, the regimen was adjusted to intraperitoneal cefepime and amikacin. After 72 hours, the VITEK® 2 automated system identified A. salmonicida with 98% probability. The patient showed clinical and laboratory improvement after 14 days of targeted therapy. Human infections caused by A. salmonicida are exceptionally rare. This case highlights the importance of considering atypical pathogens in immunocompromised patients with peritonitis. Given the challenges in its identification, the use of automated or molecular diagnostic methods is recommended. Although no clear aquatic exposure was identified, the isolation of this microorganism supports the need for broad microbiological surveillance. Antimicrobial susceptibility profiles should be evaluated on a case-by-case basis.